CEO behind HIV drug Truvada grilled on $3B in profits
02:23Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.